- Home
- PHUN vs CALC Comparison
PHUN vs CALC Comparison
Compare PHUN & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | CALC |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 45.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PHUN | CALC |
|---|---|---|
| Price | $2.03 | $4.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $7.25 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 186.6K | 91.1K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,357,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $72.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.83 | $1.42 |
| 52 Week High | $6.29 | $4.50 |
Technical Indicators
Market Signals| Indicator | PHUN | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 37.17 | 72.40 |
| Support Level | $1.83 | $3.65 |
| Resistance Level | $2.13 | $4.49 |
| Average True Range (ATR) | 0.11 | 0.33 |
| MACD | 0.01 | 0.13 |
| Stochastic Oscillator | 37.50 | 86.31 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.